TITLE

Surfaxin to Prevent RDS

PUB. DATE
May 2012
SOURCE
Monthly Prescribing Reference;May2012, Vol. 28 Issue 5, pA-8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information that Surfaxin, a peptide surfactant, from Discovery Laboratories Inc. has been approved for prevention of high-risk premature infants with respiratory distress syndrome (RDS).
ACCESSION #
74965953

 

Related Articles

  • Possible treatment for RDS.  // British Medical Journal;8/12/1978, Vol. 2 Issue 6135, p455 

    Examines the treatment for respiratory distress syndrome (RDS). Main component of natural surfactant; Cause of RDS; Transition temperature of dipalmitoyl phosphatidylcholine.

  • Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Baroutis, Georgios; Kaleyias, Joseph; Liarou, Theodora; Papathoma, Eugenia; Hatzistamatiou, Zoe; Costalos, Christos // European Journal of Pediatrics;2003, Vol. 162 Issue 7/8, p476 

    .The aim of the study was to compare the treatment regimen of three natural surfactants of different extraction and formulation (Alveofact [Surfactant A = SA], Poractant [Surfactant B = SB] and Beractant [Surfactant C = SC]) in neonatal respiratory distress syndrome (RDS). Premature infants of...

  • Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial. Tubman, T.R.J.; Halliday, H.L.; Normand, C. // BMJ: British Medical Journal (International Edition);10/13/90, Vol. 301 Issue 6756, p842 

    Estimates the cost of porcine surfactant treatment for babies with severe respiratory distress syndrome in Belfast, Northern Ireland. Citation om complications of the treatment; Provision of surfactants by the Karolinska Institute; Tendency of these babies to stay long in hospitals.

  • Temple speaks out on ethical issues with pediatric trial. Dickinson, James G. // Medical Marketing & Media;Apr2001, Vol. 36 Issue 4, p32 

    Focuses on the ethical implications of conducting the placebo-control trial of surfactants in Latin America. High mortality rate of premature newborn infants; Treatment of the respiratory distress syndrome in premature neonates; Availability of marketed surfactants in the country.

  • Placebo Effect.  // Pharmaceutical Executive;Jul2001, Vol. 21 Issue 7, p106 

    Reports on the criticism against the plan of Discovery Laboratories to test Surfaxin, a treatment for respiratory distress syndrome, in Latin America. Action taken by the company in response to the criticism.

  • Urine Output in Infants with Respiratory Distress Syndrome Treated with Surfactant. Hamdan, A. H.; Shaw, N. J. // Clinical Pediatrics;Jul2000, Vol. 39 Issue 7, p421 

    Provides information on a study which determined the time and onset of diuresis in infants with respiratory distress syndrome treated with surfactant. Patients and methods; Presentation of results; Discussion of findings; Conclusions.

  • Comparison of Curosurf versus Surfacten in the Treatment of Respiratory Distress Syndrome. Jeong Nam Kim; Eun Jung Shim // Neonatal Medicine;May2013, Vol. 20 Issue 2, p207 

    Purpose: The goal of this study was to compare the effects of treatment of newborn babies with two different surfactants, Curosurf® and Surfacten®. Methods: We retrospectively reviewed the medical records from 2007 to 2009 and divided the patients into two groups: those who received...

  • Surfactant replacement and open lung concept -- Comparison of two treatment strategies in an experimental model of neonatal ARDS. Hilgendorff, Anne; Aslan, Ece; Schaible, Thomas; Gortner, Ludwig; Baehner, Thorsten; Ebsen, Michael; Kreuder, Jochen; Ruppert, Clemens; Guenther, Andreas; Reiss, Irwin // BMC Pulmonary Medicine;2008, Vol. 8, Special section p1 

    Background: Several concepts of treatment in neonatal ARDS have been proposed in the last years. The present study compared the effects of open lung concept positive pressure ventilation (PPVOLC) with a conventional ventilation strategy combined with administration of two different surfactant...

  • Early Surfactant Therapy With Nasal Continuous Positive Airway Pressure or Continued Mechanical Ventilation in Very Low Birth Weight Neonates With Respiratory Distress Syndrome. Najafian, Bita; Fakhraie, Seyed Hasan; Afjeh, Seyed Abulfazl; Kazemian, Mohammad; Shohrati, Majid; Saburi, Amin // Iranian Red Crescent Medical Journal;Apr2014, Vol. 16 Issue 4, p1 

    Background: Various strategies have been suggested for the treatment of respiratory distress syndrome (RDS). Objectives: The aim of this study was to compare the efficacies of two common methods of RDS management among neonates with low birth weight. Patients and Methods: A cohort study was...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics